Medivir AB has announced plans to discontinue development of one type of hepatitis C virus drug in order to concentrate exclusively on nucleotide-based polymerase inhibitors. It will discontinue work on NS5A replication complex inhibitors. ---Subscribe to MedNous to access this article--- Clinical Research Company News
